Alkem Labs Q3 Profit Grows 1.6% Amidst Bold MedTech Acquisition

OTHER
Whalesbook Logo
AuthorSatyam Jha|Published at:
Alkem Labs Q3 Profit Grows 1.6% Amidst Bold MedTech Acquisition
Overview

Alkem Laboratories reported a 10.7% year-on-year revenue increase to ₹3,736.8 crore for Q3 FY26, with international sales showing strong 26.6% growth. Net profit grew a modest 1.6% to ₹636 crore, impacted by an exceptional item related to labour codes. The company announced a strategic move into the MedTech sector by acquiring a 55% majority stake in Swiss firm Occlutech for approximately ₹1,074 crore. This diversification aims to tap into the growing medical device market, with Occlutech projected to generate significant revenue in the coming years. However, Alkem faces a potential delay in its Denosumab biosimilar launch due to ongoing litigation with Amgen.

Alkem Laboratories Surges Ahead with Q3 Growth and Strategic MedTech Leap

Alkem Laboratories has unveiled its financial results for the third quarter of FY26, reporting a healthy 10.7% year-on-year (YoY) increase in revenue to ₹3,736.8 crore. The company's international sales were a standout performer, surging by 26.6% YoY, while domestic sales saw a more moderate 5.5% growth. Despite the robust top-line performance, net profit grew at a slower pace of 1.6% YoY, reaching ₹636 crore. This was partly due to an exceptional item of ₹52.8 crore related to the notification of India's Labour Codes.

Diversification into MedTech: The Occlutech Acquisition

The most significant announcement alongside the earnings was Alkem's strategic entry into the Medical Technology (MedTech) sector through the acquisition of a 55% majority stake in Occlutech Holding AG, a Swiss-based global medical device company. This move, executed through Alkem's subsidiary Alkem MedTech, involves an investment of approximately ₹1,074 crore (EUR 99.40 million). Occlutech, a leading player in minimally invasive cardiac implants, is Europe's second-largest and the world's third-largest in its segment. The acquisition aims to tap into India's MedTech market, which is projected to grow substantially, potentially reaching $50 billion by 2030.

Alkem plans to integrate Occlutech, which is already EBITDA positive and boasts a gross margin of about 73%. The company intends to refinance Occlutech's existing debt of ₹450-500 crore at a higher interest rate to a more favourable 5-6%. Management projects Occlutech to generate around ₹1,000 crore in revenue within 3-5 years, with its PFO product expected to launch in the US around June 2027.

Financial Snapshot and Outlook

For Q3 FY26, Alkem reported EBITDA of ₹828 crore, a 9% YoY increase, with an EBITDA margin of 22.2%. R&D expenses stood at 3.7% of revenue. Management expressed optimism for the domestic business, aiming to grow 100-150 basis points above the Indian Pharmaceutical Market (IPM) growth rate. The MedTech market in India is seen as a significant opportunity, and Alkem plans to focus on ortho and cardio segments globally. Both Enzene and Alkem MedTech (including Occlutech) are targeted to achieve EBITDA margins of 25% within 4-5 years.

Risks on the Horizon: Denosumab Litigation

An investor concern stems from ongoing litigation. Amgen has filed patent infringement lawsuits against Alkem and its subsidiaries concerning Alkem's planned biosimilar versions of Amgen's Denosumab products (Prolia/Xgeva). Despite an FDA inspection currently underway, the entry of Alkem's Denosumab biosimilar into the US market might be delayed beyond 2026 due to this legal challenge. This litigation could impact a key growth driver for Alkem's biosimilar portfolio.

Peer Comparison

Alkem's Q3 performance, with 10.7% revenue growth, aligns with its peers. In Q3 FY24, Sun Pharmaceutical Industries reported a 10.5% YoY revenue increase to ₹13,675.46 crore, with a net profit growth of 13.8%. Cipla also showed strong growth, with Q3 FY24 revenue up 13.66% to ₹6,603.81 crore and net profit rising 31.83%. Dr. Reddy's Laboratories reported a 16% YoY revenue increase to ₹8,358.6 crore for Q3 FY24-25, though net profit saw only a 2% YoY increase. While Alkem's profit growth was modest, its strategic diversification into MedTech sets it apart from many traditional Indian pharmaceutical players. Competitors like Sun Pharma have also been focusing on specialty products and global markets, indicating a trend towards expanding beyond core generics.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.